• 
  M Duchmann, B Braun, J.B. Micol, P Platzbecker, P. Park, et al.. Validation of response assessment according to international consortium for MDS/MPN criteria in chronic myelomonocytic leukemia treated with hypomethylating agents. Blood Cancer Journal, 2017, 7 (5), pp.e562. ⟨10.1038/bcj.2017.41⟩. ⟨hal-01655936⟩
• 
  Valérie Glorian, Jennifer Allègre, Jean Berthelet, Baptiste Dumetier, Pierre-Marie Boutanquoi, et al.. DNA damage and S phase-dependent E2F1 stabilization requires the cIAP1 E3-ubiquitin ligase and is associated with K63-poly-ubiquitination on lysine 161/164 residues.. Cell Death and Disease, 2017, 8 (5), pp.e2816. ⟨10.1038/cddis.2017.222⟩. ⟨hal-01542105⟩
• 
  Sasha Bernatsky, Héctor a Velásquez García, John J Spinelli, Patrick Gaffney, Karin E Smedby, et al.. Lupus-related single nucleotide polymorphisms and risk of diffuse large B-cell lymphoma. Lupus science & medicine, 2017, 4 (1), pp.e000187. ⟨10.1136/lupus-2016-000187⟩. ⟨hal-01726625⟩
• 
  C. Rossi, J.N. Bastie. Actualités thérapeutiques dans les lymphomes non hodgkiniens et le lymphome de Hodgkin. La Revue de Médecine Interne, 2019, 40 (4), pp.246-254. ⟨10.1016/j.revmed.2018.04.015⟩. ⟨hal-01820964⟩
• 
  Alice Cleynen, R. Szalat, M. Kemal Samur, S. Robiou Du Pont, L. Buisson, et al.. Expressed fusion gene landscape and its impact in multiple myeloma. Nature Communications, 2017, 8 (1), pp.1893. ⟨10.1038/s41467-017-00638-w⟩. ⟨hal-01697367⟩

16

61